Vir Biotechnology, Inc.
Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow VIR
Vir Biotechnology, Inc. (VIR) Altman Z-score
Vir Biotechnology, Inc.'s Altman Z-score for fiscal 2025 is −0.57, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.57 | (1.68) |
| FY2024 | 1.11 | (0.93) |
| FY2023 | 2.04 | (3.35) |
| FY2022 | 5.39 | (2.78) |
| FY2021 | 8.17 | (0.19) |
| FY2020 | 8.36 | 7.10 |
| FY2019 | 1.27 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.42 | — | 0.50 | |
| Retained earnings / total assets | (1.19) | — | −1.67 | |
| EBIT / total assets | (0.48) | — | −1.58 | |
| Market value of equity / total liabilities | 3.52 | — | 2.11 | |
| Sales / total assets | 0.07 | — | 0.07 | |
| Altman Z-score | Distress zone | −0.57 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −0.97 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| SEPN Septerna, Inc. compare | 3.4× |
| MESO Mesoblast Limited compare | 3.4× |
| XNCR Xencor, Inc. compare | 1.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 0.4× |
| VIR Vir Biotechnology, Inc. | −0.6× |
| URGN Urogen Pharma compare | −5.2× |
| PVLA Palvella Therapeutics, Inc. compare | −11.5× |
| TRVI Trevi Therapeutics, Inc. compare | — |
| BHVN Biohaven Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets